Digestive System Trials

1. Age ≥ 18 years
2. Histologically confirmed adenocarcinoma of the pancreas that is surgically inoperable.
3. Patients must have had one prior chemotherapeutic regimen for advanced disease.
4. ECOG performance status 0 – 2
5. Patients must have normal bone marrow, liver and kidney function.
6. No evidence of clinically active lung disease

1. Patients must have histologically or cytologically confirmed pancreatic adenocarcinoma that is unresectable or metastatic. No prior systemic therapy for metastatic disease. Prior adjuvant therapy is permitted if completed > 6 months.
2. No duodenal or gastric wall invasion
3. No brain metastases
4. No proteinuria
5. Age > 18 years
6. ECOG performance status 0 or 1.
7. Patients must have normal bone marrow, liver and kidney function

1. Biopsy-proven inoperable locally advanced or metastatic pancreatic adenocarcinoma.
2. ECOG performance status 0-3
3. Age > 18 years
4. Able to stand unassisted
5. Must not have pacemaker or implanted defibrillator

1. ge > 18 years
2. Phase I: Patients must have a histologically confirmed solid tumor cancer which is metastatic or locally advanced and unresectable, Phase II: Patients must have advanced colorectal cancer
3. Life expectancy > 12 weeks
4. Patients must have normal bone marrow, liver and kidney function

This research study is being done to find out whether specific biological features (often called tumor markers or markers) seen in tests done on a colon tumors can be used to predict recurrence of tumors in patients with stage II colon cancer. The chemotherapy drugs given in combination in this study are 5-fluorouracil (5-FU), leucovorin and oxaliplatin. Researchers will look to see if adding bevacizumab to these other cancer-fighting agents is better for treating colon cancer patients, who may be at increased risk for recurrence based on the markers shown in their tumors. Researchers also want to see if adding bevacizumab will help prevent the cancer from coming back. 

1. A tumor that meets certain criteria for type, size and position;
2. No history of intra-abdominal metastases;
3. No perforation or obstruction of the bowel;
4. Adequate liver, kidney, and heart function and/or laboratory values;
5. No ulcers, or serious wounds or wound healing problems, bone fractures, or non-malignant systemic disease that would exclude them from the study; 
6. Biopsy of the tumor to evaluate two particular tumor markers; 
7. 18 years of age or older;

1. Patients must have esophageal cancer that has been histologically or cytologically confirmed as adenocarcinoma or squamous cell carcinoma.
2. Patients must have surgically or medically inoperable esophageal cancer and be able to receive external beam radiation therapy at study dosages for palliation of symptoms.
3. Patient must have a minimum life expectancy of four months.
4. Patients must have a baseline dysphagia grade of 3, 4 or 5.

1. Patients must have histologically confirmed biliary cancer (gallbladder cancer or cholangiocarcinoma) that is not amenable to conventional surgical approach.
2. Patients must not have received prior chemotherapy (excluding chemotherapy given as adjuvant treatment completing more than 6 months prior to entry into study).
3. Patients must have a life expectancy of at least 12 weeks.
4. Patents must have normal liver, kidney and bone marrow function.

1. Patients must have histologically documented adenocarcinoma of the colon.
2. Patients must be randomized no more than 56 days post surgery.
3. Patients with one or more synchronous primary colon cancer(s) are eligible.
4. Patients must not have received prior chemotherapy or radiation therapy for treatment of this malignancy.
5. Patients must have normal bone marrow, liver and kidney function.

1.  Patients must have histologically confirmed adenocarcinoma of the pancreas that is metastatic.
2. Patients must not have had prior chemotherapy.
3. Patients must have core or open biopsy material available for EGF-r testing.
4. Patients must have primary of metastatic lesion measurable n at least one dimension within 4 weeks prior to randomization.
5. Patients must have adequate bone marrow, liver, kidney and cardiac function.

1. Patients must have histologically documented colorectal cancer which is EGFR-positive by IHC and is metastatic. 
2. Patients must have received prior fluouropyrimidine- containing regimen for the first-line treatment of metastatic disease.
3. Patients must have failed an Oxaliplatin-regimen for metastatic disease. Failure is defined as either progression of disease (clinical or radiologic) or intolerance to the Oxaliplatin regimen.
4. Patients must have adequate recovery from recent surgery; chemotherapy and radiation therapy and at least 8 days must have elapsed.
5. Patients must have adequate bone marrow, liver and kidney function.

1. Patients must have histologically or cytologically confirmed gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction. Patients must have metastatic or inoperable locally advanced disease.
2. Patients must not have received prior chemotherapy for metastatic or recurrent disease. One course of neoadjuvant chemotherapy and/or adjuvant chemotherapy with or without radiation therapy as primary treatment is acceptable.
3. At least 4 weeks must have elapsed since prior radiation therapy and patients must have been off previous anti-cancer therapy for at least 4 weeks.
4. Patients must not have a known hypersensitivity to 5-fluorouracil or history of allergic reactions attributed to compounds of similar chemical or biologic composition to Oxaliplatin, irinotecan and Capecitabine.
5. Patients must have adequate bone marrow, liver and kidney function.

1. Patients must have biopsy proven locally advanced adenocarcinoma of the pancreas assessed to be unresectable.
2. Patients must not have received previous treatment for pancreatic cancer.
3. Patients must have a life expectancy of greater than 3 months.
4. Patients must not have metastatic disease.
5. Patients must have normal bone marrow, liver and kidney function.

1. Patients must have a histologic diagnosis of primary GIST that expresses Kit protein by immunohistochemistry and have tumor size of greater than or equal to 3 cm in maximum dimension.
2. Patients must be at least 18 years of age.
3. Patients must have undergone complete gross resection of a primary GIST within 70 days prior to registration.
4. Patients must have adequate bone marrow, kidney and liver function.

1. Patients must have histologically diagnosed adenocarcinoma of the stomach or gastroesophageal junction.

2. Patients must not have received any previous chemotherapy or radiotherapy.

3. Patients are required to have an adequate total caloric intake to allow them to maintain their post-surgical weight.

4. Patients must be evaluated by a radiation oncologist prior to enrollment to ensure that the patient is an appropriate candidate for radiation therapy.

5. Patients must have adequate cardiac function.

6. Patients must have adequate bone marrow, liver and renal function.